Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05077709
Title IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors IO Biotech
Indications

head and neck squamous cell carcinoma

urethra transitional cell carcinoma

ureter transitional cell carcinoma

lung non-small cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

IO102-IO103 + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA | ESP

Additional content available in CKB BOOST